Fig. 1From: A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatient disposition at the time of data cut-off for primary safety analysis (August 2010) in the (a) selumetinib plus docetaxel and (b) selumetinib plus dacarbazine treatment arms. BID, twice daily; ppG-CSF, primary prophylactic granulocyte-colony stimulating factorBack to article page